Mizuho lowered the firm’s price target on Abbott (ABT) to $135 from $140 and keeps a Neutral rating on the shares following the Q2 report. The firm cut estimates on the sales guidance revision. The share selloff may be overdone but a potential rebound may be gradual, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target lowered to $142 from $147 at Wells Fargo
- Abbott upgraded to Buy from Hold at Jefferies
- Abbott Laboratories Reports Strong Q2 2025 Results
- Abbott’s Earnings Call: Strong Growth Amid Challenges
- Abbott Laboratories: Temporary Challenges Amid Strong Long-Term Growth Prospects Justify Buy Rating